We provide a catalog for the effects of the human kinome on cell survival in response to 23 DNA damaging agents, selected to cover all major DNA repair pathways. By treating 313 24 kinase-deficient cell lines with ten diverse DNA damaging agents, including seven commonly 25 used chemotherapeutics, we were able to identify kinase specific vulnerabilities and 26 resistances. In order to identify novel synthetic lethal interactions, we investigate the cellular 27 response to carmustine for 25 cell lines, by establishing a phenotypic FACS assay designed 28 to mechanistically investigate and validate gene-drug interactions. We show apoptosis, cell 29 cycle, DNA damage and proliferation after alkylation or crosslink-induced damage for 30 selected cell lines and rescue the cellular sensitivity of DYRK4, EPHB6, MARK3, PNCK as a 31 proof of principle for our study. Our data suggest that some cancers with inactivated DYRK4, 32 EPHB6, MARK3 or PNCK gene could be particularly vulnerable to treatment by alkylating 33 chemotherapeutic agents carmustine or temozolomide.
DNA damage. For instance, the ATM superfamily which includes ATM, ATR and DNA-PKcs 48 (encoded by the gene PRKDC) is involved in sensing or amplifying initial signals of DNA peak of γH2AX at 48 hours of treatment (Figure 2b) . Hence, the γH2AX signal at the 48 hour 138 time point may therefore be a consequence of apoptosis in DYRK4-deficient cells. This may 139 also be the case for PNCK and PKN2 (Figure 2b) . In contrast, PRKDC-deficient cells, which 140 have a deficiency in DNA repair, showed the maximum levels of γH2AX and apoptosis early, 141 at 24 hours after treatment, followed by a slow but coinciding recovery of γH2AX and 142 apoptosis at 48 hours after treatment (Figure 2b) . A similar, albeit weaker phenotype can be 143 observed in cells deficient for CSNK1G1, EPHB6, MARK3, PRKACA (Figure 2b ).
144
Interestingly, we also observed a strong and persistent G2/M arrest in cells deficient for 145 CSNK1G1 or EPHB6 (Figure 2b) . Although the sensitivity of these kinase-deficient cells to 146 alkylating agents revealed in our assay is as of yet unreported, it is in line with what is known 147 about their function: CSNK1G1 has previously been reported to regulate the kinase CHK1, 148 which is a cell cycle regulator following DNA damage 38 whereas EPHB6 has been linked to 149 the regulation of NPAT, a DNA damage signaling and cell cycle regulator 39 .
151
After confirming selected cellular survival phenotypes in our phenotypic screen, we next 152 sought to validate gene-drug interactions in knockout cell lines by reconstitution of the wild-153 type genes. We selected the understudied kinases, DYRK4, EPHB6, PNCK and MARK3, as 154 well as control kinases with resistance phenotypes, ABL1 and TSSK3 (Figure 1h 294 61, 1957-1963 (2001 (40) Atypical (22) CAMK (42) CK1 (6) AGC (39) Other (49) RGC (1) 
